Bayer’s asundexian meets primary efficacy and safety endpoints in landmark phase III OCEANIC-STROKE study in secondary stroke prevention: Berlin Tuesday, November 25, 2025, 11:0 ...
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...
Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.
Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...
Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...
Clinical Trials Arena on MSN
Bayer reports positive results from Phase III OCEANIC-STROKE study
The trial met its main safety and efficacy endpoints in participants who experienced a non-cardioembolic ischemic stroke.
Bayers experimental stroke treatment, asundexian, delivered strong results in the Phase III OCEANIC-STROKE trial, prompting ...
Investing.com -- Bayer’s (ETR:BAYGN) experimental stroke drug could generate €3 billion in annual sales after successful trial results that Goldman Sachs analyst James Quigley called "transformational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback